

July 19, 2022

Notice concerning the Start of Investment Business of Ono Digital Health Investment, GK

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “ONO”) announced the establishment and start of an investment business of Ono Digital health Investment, GK (“ODHI”) as a corporate venture capital (CVC) that invests in venture companies in the field of healthcare, other than the ethical pharmaceutical drug-related field.

With growing interest in the healthcare field, the number of venture companies are increasing to solve health-related social issues, such as disease prevention and improvement of quality of life (QOL), by using digital technology. Through ODHI, our wholly-owned CVC, ONO will provide new value in the healthcare field by co-creating with venture companies that utilize digital technology.

ODHI will make investments in venture companies regardless of their business stage or location. Through collaborations and other initiatives between promising venture companies both in Japan and overseas and Ono’s affiliates, we are committed to extending healthy life expectancy and realizing a sustainable society.

Ono Venture Investment, Inc. (<https://www.onoventure.com/>), a CVC established in the US in May 2020, will continue to invest in bio-venture companies related to drug discovery.

Summary of Ono Digital health Investment

Company	Ono Digital health Investment, GK.
Location	9-11, Nihonbashi-Honcho 4-chome, Chuo-ku, Tokyo
Establishment	March 2022
Representative	Masaki ITO, Operating Officer/President
No. of Staff	3 persons
Business	Investment in venture companies in the healthcare field, etc.
Capital	10 million yen
Relationship	A wholly-owned subsidiary of ONO
Investment size	5 billion yen (Including the amount of investment before establishment)
Homepage	https://www.onodigitalhealth.com/en
Contact	info-onodigi@ono.co.jp

(Future outlook)

An impact of this matter on the Company's financial business results for the current fiscal year would be marginal. Should there be any events to be disclosed in the future, we will announce them in a timely manner.

Contact:

Ono Pharmaceutical Co., Ltd.
Corporate Communications
public_relations@ono.co.jp